Hansoh Pharmaceutical's (HKG:3692) new drug application for HS-10568 Injection was accepted by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.
The acceptance is for use of the drug secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing hemodialysis.